Mitral Valve Disease

Current Location

15 Mitral Valve Disease Trials Near You

Power is an online platform that helps thousands of Mitral Valve Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

TMVR for Mitral Valve Regurgitation

Columbus, Ohio
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1056 Participants Needed

Carillon Device for Heart Failure with Mitral Regurgitation

Columbus, Ohio
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

Transcatheter Valve Repair for Mitral Regurgitation

Cincinnati, Ohio
This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1247 Participants Needed

Foldax TRIA Heart Valve for Mitral Valve Disease

Cincinnati, Ohio
This trial is testing a new artificial heart valve made from special plastic. It is for patients who need a replacement for their faulty mitral valve. The new valve is implanted through surgery to help the heart work better.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

15 Participants Needed

Tendyne Transcatheter Mitral Valve System for Mitral Regurgitation

Cincinnati, Ohio
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

958 Participants Needed

SAPIEN M3 System for Mitral Regurgitation

Detroit, Michigan
This trial will test the safety and effectiveness of the SAPIEN M3 System in patients with severe mitral regurgitation. The device is designed to help the heart valve close properly, preventing blood from flowing backward. The study aims to gather information for future research on this treatment. The SAPIEN M3 System is part of the SAPIEN family of heart valves, which have been used in various applications including aortic and mitral valve replacements.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

72 Participants Needed

Transcatheter Mitral Valve Replacement for Mitral Valve Disease

Detroit, Michigan
To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

53 Participants Needed

Transseptal ViMAC for Mitral Valve Disease

Detroit, Michigan
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

185 Participants Needed

Mobile Health Exercise Regimen for Heart Valve Disease

Nashville, Tennessee
The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off/interactive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

375 Participants Needed

TMVR for Mitral Valve Disease

Hershey, Pennsylvania
The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

75 Participants Needed

Millipede System for Mitral Regurgitation

Atlanta, Georgia
To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

4 Participants Needed

SESAME Procedure for Hypertrophic Cardiomyopathy

Atlanta, Georgia
Background: Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO. Objective: To test a new procedure where excess tissue is sliced away from the septum in people with LVOTO. This procedure is called "septal scoring along midline endocardium" (SESAME). Eligibility: Adults aged 21 years with LVOTO. Design: Participants will have baseline tests. They will have imaging scans and tests of their heart structure and function. They will take a walking test and answer questions about how their heart condition affects their life. Participants will stay in the hospital 2 to 6 days for the SESAME procedure. They will be completely or partially asleep for the procedure. A tube will be inserted into the mouth and down the throat to take pictures of the heart. Pictures may also be taken with a tube inserted inside the heart. Next, tubes will be inserted into the groin and guided through the blood vessels up to the heart. Guidewires will be inserted into the heart. Doctors will watch the path the wires take with x-rays and ultrasound. When the wire is in the correct place, it will be electrified to slice excess tissue away from the septum. Participants will have 3 follow-up visits within 1 year.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 99

30 Participants Needed

Percutaneous vs Surgical Mitral Valve Repair for Mitral Valve Regurgitation

Ottawa, Ontario
Ischemic mitral regurgitation (MR) and coronary artery disease is common and associated with significant morbidity and mortality. Ischemic MR has been traditionally treated surgically through either valve repair or replacement at the time of concomitant bypass grafting. Although patients with ischemic MR represent a heterogeneous group, outcomes for these patients over the intermediate term is poor owing to left ventricle (LV) dysfunction causing MR and the presence of coronary disease, which portends poor survival. There is an emergence of percutaneous therapies to treat MR which have been shown to be a less invasive, safe, and viable approach to treat comorbid patients. The decision to treat ischemic MR either surgically or percutaneously is influenced by the presence of coronary disease and the ability to provide adequate revascularization. Mitral valve surgery concomitant to surgical revascularization, however, is associated with a several fold increase in mortality. In fact, the incremental risk increase is further magnified in high-risk patients. We therefore propose a novel prospective study to guide intervention for ischemic MR. Patients will be randomized to undergo surgical therapy with either mitral repair/replacement and/or concomitant coronary artery bypass grafting OR percutaneous mitral repair, followed by coronary artery bypass grafting.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

Mitral Valve Repair for Mitral Valve Regurgitation

Ottawa, Ontario
Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death. Patients with MR can be divided in two broad groups: those with primary MR, caused by disease of the mitral valve structures, and those with secondary MR, due to dilation of the heart chambers. Our study focuses on patients with primary MR. The standard treatment for severe symptomatic primary MR is mitral valve surgery, a type of open-heart surgery. The outcomes following this procedure are excellent, however, a subset of patients continue to experience heart failure symptoms after surgery due to very high pressures in the heart, more specifically in the left atrium, which is one of the four heart chambers. This is called functional mitral stenosis (FMS). Previous studies have shown that creating a small opening between the left and right atria can help relieve the pressure inside the left atrium. We would like to determine whether creating this opening between the two atria at the time of mitral valve surgery can help prevent FMS. To answer this question, we will study two groups of patients who need mitral valve surgery for primary MR. The first group will undergo mitral valve surgery, along with the creation of the opening between the two atria. The second group will undergo mitral valve surgery alone. We will then compare the outcomes between both groups, namely with regards to their heart failure symptoms after open-heart surgery.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

50 Participants Needed

Automatic Prompts for Aortic Stenosis

Ottawa, Ontario
Echo Prompts study is a multi-center randomized controlled study to evaluate the impact of automatic prompts added to the conclusion of the echocardiographic reports of patient diagnosed with significant VHD 1) suggesting referral to a cardiologist or 2) suggesting referral to a cardiologist and offering the help of the University of Ottawa Heart Institute Center for Valvular Heart Diseases, compared to current standard of care (no prompts) on the rates and time to an evaluation by a cardiologist. We plan to involve a total of 300 patients in total. Primary endpoint will be the rate of referrals of patients having VHD to a cardiologist within 6 months after their TTE.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

300 Participants Needed

Why Other Patients Applied

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Mitral Valve Disease clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Mitral Valve Disease clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Mitral Valve Disease trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Mitral Valve Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Mitral Valve Disease medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Mitral Valve Disease clinical trials?

Most recently, we added Automatic Prompts for Aortic Stenosis, SESAME Procedure for Hypertrophic Cardiomyopathy and Mitral Valve Repair for Mitral Valve Regurgitation to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

15 Depression Trials near Charlotte, NC

Top Clinical Trials near Dinuba, CA

Top Clinical Trials near Alexandria, LA

Top Clinical Trials near Alexander City, AL

Top Colorectal Cancer Clinical Trials near Las Vegas, NV

122 Clinical Trials near Crown Point, IN

12 Glaucoma Trials near San Antonio, TX

58 Alzheimer's Disease Trials near Orlando, FL

170 Transcranial Magnetic Stimulation Trials Near You

Top Clinical Trials near Basalt, CO

22 Leiomyosarcoma Trials near Miami, FL

Top Alcoholism Clinical Trials

By Trial

Lenacapavir for HIV Prevention

Cancer Vaccine + Nivolumab + Ipilimumab for Liver Cancer

Advanced Prosthetic Control Algorithm for Limb Weakness

Psilocybin for Psychological Distress in Pancreatic and Biliary Tract Cancer

SBRT for Adenoid Cystic Carcinoma

Cellular Therapy for Bronchopulmonary Dysplasia

Limonene Metabolism and CYP2C19 Genetic Variants

CBD for Knee Osteoarthritis

Cognitive Behavioral Therapy for Social Anxiety Disorder

Enhanced Screening for Lung Cancer

Exercise for Breast Cancer

Mitochondrial Transplant for Stroke

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial